Saunders Scott J 4

What Happened

• Scott J. Saunders, a director of Nutex Health, was granted 603 restricted stock units (RSUs) on July 14, 2025. The grant is recorded as a derivative award at $0.00 per share (total cash paid at grant = $0). This is an equity compensation grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: July 14, 2025; grant price reported: $0.00 per RSU.
• Award size: 603 RSUs (each RSU converts to one share upon vesting).
• Vesting: 100% vests on July 14, 2026 (see footnote: pro‑rata vesting if the director leaves without cause during vesting period).
• Shares owned following the transaction: not reported in this filing.
• Filing date: February 9, 2026 — the Form 4 was filed well after the grant date (late filing), which delays public transparency about the award.

Context

• RSUs are a contingent right to receive common stock upon vesting; they do not represent immediate transferable shares. Taxation and ownership typically occur at vesting (or when shares are delivered).
• Grants to directors are common as compensation and do not necessarily signal buying or selling intent by the insider. This transaction is compensation-related rather than a market purchase.